Top Story

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014

The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent high-dose chemotherapy and autologous stem cell transplantation, according to results of a randomized, phase 3 trial.

The analysis included 362 patients with myeloma who melphalan conditioning followed by autologous stem cell transplantation at Heidelberg University Hospital in Germany. All patients were aged 18 years or older.

In the Journals

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as vice president…
figure In the Journals

CTL019 therapy conferred 90% remission rate in relapsed, refractory ALL

October 15, 2014
Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and refractory acute…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »

Filter By:

In the Journals

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014
The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent…
In the Journals

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as…
figure In the Journals

CTL019 therapy conferred 90% remission rate in relapsed, refractory ALL

October 15, 2014
Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and…
figure FDA News

FDA grants priority review to blinatumomab for ALL

October 10, 2014
The FDA granted priority review status to blinatumomab, an investigational agent intended for the treatment of adults with Philadelphia…
FDA News

FDA approves Velcade regimen for treatment-naive mantle cell lymphoma

October 9, 2014
The FDA today approved the use of bortezomib as part of a combination regimen for patients with previously untreated mantle cell lymphoma, the…
In the Journals

White blood cell recovery predicted OS, PFS after HCT

HemOnc Today, October 25, 2014
A scoring system based on the pattern of peripheral white blood cell recovery within the first 3 months after allogeneic hematopoietic cell…
figure Institution Notes

Cancer center names director of BMT

HemOnc Today, October 25, 2014
William Tse, MD, has been named director of bone marrow transplantation at the University of Louisville James Graham Brown Cancer Center.Tse also…
figure Cover Story Publication Exclusive

Multiple TKIs for first-line CML treatment ‘a mixed blessing’

HemOnc Today, October 25, 2014
The treatment landscape for most blood cancers has evolved rapidly during the past decade, and chronic myeloid leukemia is no exception.Imatinib…
figure Meeting News Coverage

International Myeloma Foundation addresses Congress on toxins at Ground Zero

September 30, 2014
On Sept. 10, the International Myeloma Foundation hosted a congressional briefing to raise awareness on the connection between environmental exposure…
More Headlines »